− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood ...

Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...

Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...

Molecular details of ADAMTS13 binding by autoantibodies reveal, for the first time, the mechanism of inhibition of ADAMTS13 by those autoantibodies and suggest an avenue for therapeutic intervention.

Shire announced that the FDA has granted Fast Track designation to SHP655 (historically BAX930) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

The U.S. Food and Drug Administration (FDA) on Friday said it has received postmarketing reports of neutralizing antibodies to ADAMTS13 in patients treated with Adzynma (recombinant ADAMTS13), ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda’s Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency ...